Silo Pharma, Inc. - Common Stock (SILO)

Silo Pharma reported positive preclinical results for its ketamine-based implant SP-26, designed to treat chronic pain and fibromyalgia.

With developmental-stage Silo Pharma inking a partnership to forward PTSD drugs, SILO stock shot higher on the credibility boost.

Silo Pharma Inc.'s stock (NASDAQ: SILO) is on the the rise Wednesday following the company's announcement that it has been awarded a U.S. patent for its PTSD treatment titled "Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females."

Silo Pharma stock is rising after announcing a collaboration with Kymanox to develop a subcutaneous insertion device for its SP-26 chronic pain treatment.

Silo Pharma stock soared on high trading volume after announcing a partnership with Resyca BV for developing an intranasal PTSD treatment. The collaboration aims to enhance drug delivery to the brain, for faster therapeutic benefits and improved safety.